Herpes zoster prevention

Vaccine, Recombinant

Duration:~85% to 93% vaccine efficacy after 4 years

Severe hypersensitivity (eg, anaphylaxis) to recombinant zoster vaccine or any component of the formulation.

consideration be given to delaying vaccination with zoster vaccine (recombinant) during pregnancy

It is not known if components of this vaccine are present in breast milk. In general, administration of recombinant vaccines does not affect the safety of breastfeeding for the mother or the infant

Common(>10%):
Gastrointestinal: GI adverse effects (13% to 24%)
Local: Erythema at injection site (20% to 39%), pain at injection site (69% to 88%), swelling at injection site (10% to 31%)
Nervous system: Fatigue (37% to 57%), headache (15% to 51%), shivering (11% to 36%)
Neuromuscular & skeletal: Myalgia (35% to 57%)
Miscellaneous: Fever (6% to 28%; including high fever)
1% to 10%:
Dermatologic: Injection site pruritus (2%)
Gastrointestinal: Nausea (1%)
Nervous system: Chills (4%), dizziness (1%), malaise (2%)
Neuromuscular & skeletal: Arthralgia (2%)
Respiratory: Flu-like illness (1%), pneumonia (2%)
<1%:
Endocrine & metabolic: Gout (including gouty arthritis)
Hematologic & oncologic: Lymphadenitis
Ophthalmic: Optic neuropathy
Post marketing:
Dermatologic: Skin rash, urticaria
Hypersensitivity: Angioedema, hypersensitivity reaction
Nervous system: Guillain-Barre syndrome , impaired mobility

1.Shingles prevention::
Adults ?18 years of age(immunocompromised [current or future]):
IM: 0.5 mL administered as a 2-dose series at 0 and 1 to 2 months.
Adults ?50 years of age (immunocompetent):
IM: 0.5 mL administered as a 2-dose series at 0 and 2 to 6 months.

Safety and efficacy have not been established in patients younger than 18 years

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling

保存在攝氏 2°C 至 8°C，不得冷凍